Printer Friendly
The Free Library
19,607,059 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Avigen, Inc. Announces Year-End 2007 Earnings Conference Call.


Avigen to Host Conference Call Wednesday, February 6, at 1:00 p.m. ET

ALAMEDA, Calif. -- Avigen, Inc. (Nasdaq:AVGN AVGN Angry Video Game Nerd ), a biopharmaceutical company innovating therapeutics for neurological care, will hold its quarterly conference call to discuss year-end results on Wednesday, February 6, 2008, at 1:00 p.m. ET (10:00 a.m. PT). Kenneth Chahine, Chief Executive Officer, and Michael Coffee, Chief Business Officer, can be heard by calling 888-713-4205 (U.S.) or 617-213-4862 (non-U.S. locations) using passcode 16083697.

This call is being webcast by Thomson/CCBN and can be accessed at Avigen's website at www.avigen.com. The webcast is also being distributed through the Thomson StreetEvents Network. Individual investors can listen to the call at www.earnings.com, Thomson's individual investor portal, powered by StreetEvents. Institutional investors Institutional Investor

A non-bank person or organization that trades securities in large enough share quantities or dollar amounts that they qualify for preferential treatment and lower commissions.
 can access the call via Thomson StreetEvents (www.streetevents.com), a password-protected event management site.

A rebroadcast of the call will be available shortly after the conclusion of the session. The replay may be accessed over the Internet at www.avigen.com or by calling 888-286-8010 (U.S.) or 617-801-6888 (non-U.S. locations) using passcode 57208063.

About Avigen

Avigen, Inc. is a biopharmaceutical company focused on unique small molecule therapeutics and biologics to treat serious, chronic neurological disorders This is a list of major and frequently observed neurological disorders (e.g. Alzheimer's disease), symptoms (e.g.back pain), signs (e.g. aphasia) and syndromes (e.g. Aicardi syndrome). , including neuropathic neuropathic /neu·ro·path·ic/ (-path´ik) pertaining to or characterized by neuropathy.

neuropathic

pertaining to disease of the nervous system.
 pain and neuromuscular neuromuscular /neu·ro·mus·cu·lar/ (-mus´ku-ler) pertaining to nerves and muscles, or to the relationship between them.

neu·ro·mus·cu·lar
adj.
1.
 spasm and spasticity spasticity /spas·tic·i·ty/ (spas-tis´i-te) the state of being spastic; see spastic (2).

spas·tic·i·ty
n.
1. A spastic state or condition.

2. Spastic paralysis.
. For press releases and other corporate information, visit our website at www.avigen.com.
COPYRIGHT 2008 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2008, Gale Group. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jan 30, 2008
Words:231
Previous Article:Staples, Inc. Names Mark Mettler Senior Vice President, Merchandising.
Next Article:Paladyne and Reuters Expand Offering to Include Hosted Reuters DataScope Onsite.
Topics:



Related Articles
Avigen licenses adeno-associated virus vector technology to Stratagene.
Avigen granted gene therapy patent for intravenous delivery of Aav vectors.
AVIGEN LICENSES POTENTIAL PARKINSON'S DISEASE TREATMENT.
Avigen issued three patents expanding AAV portfolio.
Avigen Issued patent for advanced AAV vector.
Avigen exclusively licenses technology of chronic pain.
AVIGEN REPORTS 3RD QTR NET LOSS OF $5.7 MILLION.
AVIGEN REPORTS FIRST QTR 2007 NET LOSS OF $5.8 MILLION.
AVIGEN REPORTS FIRST QTR 2008 NET LOSS OF $7.4 MILLION.
AVIGEN REPORTS NET LOSS OF $7.3 MIL FOR 2ND QTR 2008.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles